![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Gilead Sciences Prices Remdesivir at $520 Per Vial
Gilead Sciences Prices Remdesivir at $520 Per Vial
![GILEAD.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/GILEAD.gif?t=1580164042&width=430)
Gilead Sciences has announced that the price it will charge U.S. insurers for remdesivir, its antiviral treatment for COVID-19 patients, is $520 per vial and $3,120 for a six-vial, five-day course of treatment.
However, the California drugmaker said the governments of developed countries, including the U.S., will pay $390 per vial and $2,340 for a six-vial, five-day course of treatment.
Gilead also announced that HHS will continue to manage distribution of remdesivir until the end of September.
Upcoming Events
-
21Oct